Developer docs
API playgroundTry for free, no card

Search company profiles

GI CELL

Full company profile

uuid000egax

Namestring
GI CELL
Legal namestring
주식회사 지아이셀 (GI CELL Inc.)
Websiteurl
gi-cell.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

GI CELL (주식회사 지아이셀) is a clinical-stage South Korean biotechnology company founded in October 2018 in Seongnam, Gyeonggi-do, as a subsidiary of GI Innovation (지아이이노베이션). The company develops immune cell therapies for cancer and autoimmune diseases, anchored by a proprietary dual-function cytokine fusion protein platform — branded as the Immune CellPure Expander — which underpins the NKPURE Expander® (feeder-cell-free, non-genetically-modified allogeneic NK cell production) and TregPure Expander™ (regulatory T cell expansion) sub-platforms. In February 2022, GI CELL achieved a world-first 200L bioreactor scale-up of NK cells, a milestone that anchors its differentiated manufacturing position, with one batch capable of yielding up to 400 vials of clinical product at 1 billion NK cells per dose.

The clinical pipeline comprises T.O.P. NK (GIC-102, an off-the-shelf NK therapy in Phase 2a for solid tumors and hematologic cancers), Nano NK (GIC-101, NK cells carrying drug-loaded nanoparticles for solid tumor targeting), Drone Treg (GIC-302, tissue-homing Tregs for inflammatory bowel disease), and a CAR-NK program developed in collaboration with HK inno.N and Y-Biologics. Phase 1 results reported tumor reduction in a heavily pretreated rectal cancer patient and complete remission in a lymphoma patient who had failed prior antibody and targeted therapy. GI CELL holds MFDS manufacturing and human cell management licenses, operates a ~3,400 m² GMP smart factory, and has secured patent protection in 8+ countries including Korea, EU, Japan, Taiwan, and the US.

GI CELL's revenue model is built on three pillars: (1) technology out-licensing with upfront fees, milestone payments, and double-digit royalties (exemplified by the November 2024 TCT Health Technologies LOI for Turkey and CIS countries); (2) CDMO services leveraging the GMP facility for third-party cell therapy manufacturing; and (3) future pharmaceutical commercialization of proprietary cell therapy candidates either independently or through co-development partnerships. The company is pre-revenue and has been funded primarily through Korean VC channels, with Daily Partners as lead investor across seed, Series A (26B KRW), and Series B (50B KRW) rounds, plus follow-on participation from Aju IB, Cloud IB, JW Partners, Kiwoom Securities, and Brain Asset Management, totaling approximately 1.2 trillion KRW (~$900M) in cumulative funding.

Short descriptiontext

GI CELL is a South Korean clinical-stage biotechnology company developing allogeneic NK cell and regulatory T cell therapies for solid tumors, hematologic cancers, and autoimmune diseases using proprietary feeder-cell-free, dual-cytokine expansion platforms and a GMP smart factory.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy development, NK cell therapy, immune cell therapies, regenerative medicine, allogeneic cell therapy
Industry5 codes
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy / Cancer Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing / Out-licensing
TypeLicensing Royalties
Description

GI CELL generates revenue by licensing its proprietary NK cell culture technology and T.O.P. NK® platform to international partners. The company receives upfront non-refundable contract fees upon signing, ongoing milestone payments tied to development and regulatory achievements, and double-digit royalties on net sales. Example: Technology export agreement with Turkey's TCT Health Technologies.

gi-cell.com
2CDMO (Contract Development and Manufacturing Organization) Services
TypeProfessional Services
Description

GI CELL operates its GMP facility for third-party cell therapy manufacturing. The company holds advanced biopharmaceutical manufacturing and human cell management licenses, enabling it to provide contract manufacturing services to other biotech companies requiring cell therapy production capabilities.

gi-cell.com
3Pharmaceutical / Drug Development
TypeOne Time License
Description

Development of proprietary cell therapy drug candidates (T.O.P. NK, Drone Treg, Nano NK, CAR-NK) targeting cancer and autoimmune diseases. Revenue would be generated upon regulatory approval and commercialization, either independently or through co-development partnerships.

gi-cell.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

GI CELL develops allogeneic (off-the-shelf) immune cell therapies, primarily natural killer (NK) cell and regulatory T cell (Treg) therapies, for the treatment of cancer and autoimmune diseases. The company leverages proprietary feeder-cell-free, non-genetically-modified cell expansion platforms (NKPURE Expander, TregPure Expander, Immune CellPure Expander) to manufacture cell therapy products at commercial scale (world's first 200L NK cell culture). Revenue is generated through technology licensing and out-licensing deals, CDMO services using its GMP-certified smart factory, and planned commercialization of cell therapy drug candidates including T.O.P. NK (GIC-102), GIC-101 (Nano NK), GIC-302 (Drone Treg), and CAR-NK therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • World's first successful 200L NK cell culture in February 2022
+5 more records
Product overview1 text field

GI CELL is a cell therapy development company offering a portfolio of immune cell therapy products and platforms. The core product lineup includes T.O.P. NK (GIC-102), an allogeneic NK cell therapy for solid and hematologic cancers in Phase 2a; GIC-101 (Nano NK), an enhanced NK cell therapy with nanoparticle-delivered chemotherapy for solid tumors; GIC-302 (Drone Treg), a patient-customized regulatory T cell therapy for inflammatory bowel disease; and CAR-NK, a next-generation CAR-modified NK cell therapy developed in partnership. These products are underpinned by proprietary technology platforms: the NKPURE Expander Platform (feeder-cell-free NK cell culture), the TregPure Expander Platform (Treg cell culture), and the broader Immune Cell Expander Platform (dual-fusion protein-based immune cell activation and expansion). GI CELL also offers contract development and manufacturing (CDMO) services leveraging its GMP-certified smart factory facility.

Product and service5 records
1T.O.P. NK (GIC-102)
CategoryCell Therapy / Cancer Immunotherapy
Description

Allogeneic (off-the-shelf) NK cell therapy for solid tumors and hematologic cancers, produced without feeder cells or viral vectors using the NKPURE Expander Platform. Demonstrates high tumor-targeting and cancer-cell killing efficiency. Currently in Phase 2a clinical trial in Korea after completing Phase 1 with efficacy signals including tumor reduction in a rectal cancer patient (13.5% reduction after 16 weeks) and complete remission in a lymphoma patient who had failed prior antibody and targeted therapy.

2GIC-101 (Nano NK)
CategoryCell Therapy / Cancer Immunotherapy
Description

Enhanced off-the-shelf NK cell therapy based on the T.O.P. NK platform with chemotherapeutic-loaded nanoparticles attached to the NK cell surface. Leverages NK cell tumor-homing and immunological synapse formation to achieve tumor-specific drug delivery with stronger anticancer effect against solid tumors. Developed using NKPURE Expander Platform in collaboration with POSTECH professor Kim Won-jong.

3GIC-302 (Drone Treg)
CategoryCell Therapy / Autoimmune Disease Therapy
Description

Regulatory T cell (Treg) therapy for inflammatory bowel disease and autoimmune conditions, featuring organ-homing receptors (CCR9, α4β7) overexpressed during culture and high FoxP3 expression for targeted treatment. Developed using the TregPure Expander Platform. Targets patients refractory to TNF inhibitors such as Humira and addresses Crohn's disease and ulcerative colitis.

4CAR-NK
CategoryCell Therapy / Cancer Immunotherapy
Description

Next-generation off-the-shelf CAR-NK cell therapy with chimeric antigen receptor attached, developed in collaboration with HK inno.N, Y-Biologics, and Cartexell. Leverages GI CELL's large-scale NK cell culture and mass production technology combined with partners' antibody discovery platforms for solid tumor targeting.

5CDMO Contract Manufacturing Services
CategoryContract Manufacturing Services
Description

Contract development and manufacturing organization (CDMO) services for third-party cell therapy developers, leveraging GI CELL's GMP-certified smart factory facility (~3,400 m²) and advanced biopharmaceutical manufacturing license. Provides immune cell production capabilities to biotech companies that require cell therapy manufacturing but lack their own GMP infrastructure.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-21
Description

GI CELL signed a letter of intent with TCT Health Technologies, a Turkish venture capital investment fund, for technology export of its allogeneic NK cell therapy (T.O.P. NK®). TCT will have commercialization rights in Turkey and neighboring CIS countries, bearing all development and clinical costs. GI CELL receives non-refundable upfront fees and double-digit royalties on net sales. Agreement for definitive technology transfer contract planned for March 2025. Led by Dr. Adil Mardinoglu, CSO of TCT and Professor at King's College London.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-22
Description

GI CELL and Y-Bio Logics signed a business cooperation agreement (MOU) for co-development of CAR-NK anticancer therapy candidates. Y-Bio Logics contributes its antibody discovery platform technology and nanobody library (Ymax-ABL, Ymax-Nano, pH-sensitive antibody technology, ALiCE T-cell bispecific platform) to develop novel tumor-targeting CAR-NK products combined with GI CELL's NK cell expansion and mass culture capabilities.

3OmniaMed (옴니아메드)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-11-02
Description

GI CELL participates as co-development partner in a Ministry of Trade, Industry and Energy-funded cross-disciplinary technology project with OmniaMed. OmniaMed is developing PNP (polymer nanoparticle) mRNA delivery platform technology; GI CELL contributes its NK cell therapy platform to develop next-generation allogeneic NK cell therapy with enhanced anticancer activity and in-vivo persistence through mRNA delivery technology. Project selected April 2023.

gi-cell.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-29
Description

GI CELL and HK inno.N entered a joint R&D agreement for allogeneic CAR-NK candidate development. The partnership leverages GI CELL's large-scale immune cell culture technology and HK inno.N's development and commercialization experience. Companies plan to develop multiple CAR-NK programs targeting clinical entry by 2024. HK inno.N brings GMP facilities and extensive pharmaceutical development capabilities.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-04-27
Description

GI CELL signed MOU with Helixmith and Cartexell for joint development of innovative cell therapies using the Immune Cell Expander Platform. Collaboration involves joint research on gene materials needed for cell therapy development, with potential for separate contract manufacturing agreements.

6Cartexell
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-04-27
Description

GI CELL signed MOU with Helixmith and Cartexell for joint development of innovative cell therapies using the Immune Cell Expander Platform. Collaboration involves joint research on gene materials needed for cell therapy development.

gi-cell.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-02
Description

GI Innovation, GI CELL, and Yonsei University Health System signed MOU to establish a cell therapy center at Severance Hospital and Songdo Severance Hospital. The partnership aims to build GMP facilities within hospital sites and establish a seamless process for research, production, clinical trials, and regulatory approval of advanced biopharmaceuticals including cell therapies.

8Ewha Womans University Medical Center (이화여자대학교 의료원)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-05-18
Description

GI CELL and Ewha Womans University Medical Center signed MOU for biohealth industry promotion and development. Cooperation areas include anticancer immune cell therapy translational and clinical research, COVID-19 vaccine candidate development, clinical trial consulting, and new drug co-research.

gi-cell.com
9International Vaccine Institute (IVI, 국제백신연구소)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-25
Description

GI CELL signed MOU with IVI for co-development of COVID-19 vaccine candidate. IVI facilitates international clinical development and global supply of vaccines. GI CELL contributes its vaccine development capabilities. The partnership targets vaccine development with variant responsiveness, safety, and patient convenience.

gi-cell.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-05
Description

GI Innovation, GI CELL, GI Biome, and Yonsei University College of Medicine signed MOU for innovative new drug development. GI CELL contributes immune cell therapy expertise; Yonsei contributes clinical research capabilities. Partnership includes joint research center establishment, academic conferences, and joint seminars.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing allogeneic NK cell therapies for cancer using engineered NK cells. Direct competitor in allogeneic NK cell therapy modality with overlapping target indications in solid tumors and hematologic malignancies.

TypeDirect peer
Description

Clinical-stage biotech developing off-the-shelf iPSC-derived NK cell and T-cell therapies. Closely comparable in modality (off-the-shelf allogeneic cell therapy) and target indications, with established partnerships with major pharma companies.

TypeDirect peer
Description

Clinical-stage company developing allogeneic cell therapies including NK and T cells derived from iPSCs. Direct competitor in off-the-shelf engineered cell therapy for oncology with comparable pipeline stage and target indications.

TypeDirect peer
Description

Developer of allogeneic NK cell and macrophage cell therapies derived from iPSCs. Competes directly with GI CELL in the allogeneic NK cell therapy space with platform technology focused on scalable off-the-shelf production.

TypeDirect peer
Description

Clinical-stage biotech developing allogeneic CAR-T and other engineered cell therapies using gene editing. Comparable in developing off-the-shelf cell therapies, though focused on T cells with TALEN gene editing technology.

TypeDirect peer
Description

Allogeneic T-cell immunotherapy company with marketed product Ebvallo and pipeline in oncology and autoimmune. Comparable in allogeneic off-the-shelf cell therapy modality and target indications including autoimmune disease.

TypeBroad incumbent
Description

Commercial-stage cell therapy company developing engineered T-cell therapies for solid tumors with approved product Tecelra. Broader incumbent in cell therapy space with overlapping oncology focus and established manufacturing capabilities.

TypeBroad incumbent
Description

Clinical-stage gene editing company developing gene-edited cell therapies including allogeneic CAR-T candidates. Operates more broadly across gene editing modalities but overlaps in engineered cell therapy development for oncology.

TypeBroad incumbent
Description

Established commercial cell therapy leader with approved CAR-T products Yescarta and Tecartus. Larger industry incumbent serving as both a competitor and potential acquirer/partnership target for next-generation cell therapy developers.

TypeOthers
Description

Parent company of GI CELL and developer of fusion protein-based biopharmaceuticals. Closely related entity providing the dual-function cytokine fusion protein technology that underpins GI CELL's cell expansion platforms, also a strategic partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GI CELL

Cell Therapy / Cancer Immunotherapygi-cell.com

GI CELL is a South Korean clinical-stage biotechnology company developing allogeneic NK cell and regulatory T cell therapies for solid tumors, hematologic cancers, and autoimmune diseases using proprietary feeder-cell-free, dual-cytokine expansion platforms and a GMP smart factory.

What GI CELL does

GI CELL (주식회사 지아이셀) is a clinical-stage South Korean biotechnology company founded in October 2018 in Seongnam, Gyeonggi-do, as a subsidiary of GI Innovation (지아이이노베이션). The company develops immune cell therapies for cancer and autoimmune diseases, anchored by a proprietary dual-function cytokine fusion protein platform — branded as the Immune CellPure Expander — which underpins the NKPURE Expander® (feeder-cell-free, non-genetically-modified allogeneic NK cell production) and TregPure Expander™ (regulatory T cell expansion) sub-platforms. In February 2022, GI CELL achieved a world-first 200L bioreactor scale-up of NK cells, a milestone that anchors its differentiated manufacturing position, with one batch capable of yielding up to 400 vials of clinical product at 1 billion NK cells per dose.

The clinical pipeline comprises T.O.P. NK (GIC-102, an off-the-shelf NK therapy in Phase 2a for solid tumors and hematologic cancers), Nano NK (GIC-101, NK cells carrying drug-loaded nanoparticles for solid tumor targeting), Drone Treg (GIC-302, tissue-homing Tregs for inflammatory bowel disease), and a CAR-NK program developed in collaboration with HK inno.N and Y-Biologics. Phase 1 results reported tumor reduction in a heavily pretreated rectal cancer patient and complete remission in a lymphoma patient who had failed prior antibody and targeted therapy. GI CELL holds MFDS manufacturing and human cell management licenses, operates a ~3,400 m² GMP smart factory, and has secured patent protection in 8+ countries including Korea, EU, Japan, Taiwan, and the US.

GI CELL's revenue model is built on three pillars: (1) technology out-licensing with upfront fees, milestone payments, and double-digit royalties (exemplified by the November 2024 TCT Health Technologies LOI for Turkey and CIS countries); (2) CDMO services leveraging the GMP facility for third-party cell therapy manufacturing; and (3) future pharmaceutical commercialization of proprietary cell therapy candidates either independently or through co-development partnerships. The company is pre-revenue and has been funded primarily through Korean VC channels, with Daily Partners as lead investor across seed, Series A (26B KRW), and Series B (50B KRW) rounds, plus follow-on participation from Aju IB, Cloud IB, JW Partners, Kiwoom Securities, and Brain Asset Management, totaling approximately 1.2 trillion KRW (~$900M) in cumulative funding.

GI CELL firmographics

Firmographics
Name
GI CELL
Legal name
주식회사 지아이셀 (GI CELL Inc.)
Website
https://gi-cell.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
GI CELL is a South Korean clinical-stage biotechnology company developing allogeneic NK cell and regulatory T cell therapies for solid tumors, hematologic cancers, and autoimmune diseases using proprietary feeder-cell-free, dual-cytokine expansion platforms and a GMP smart factory.
Ownership category
akta.pro rank

GI CELL industry classification

Industry
Product category
Cell Therapy / Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy development
  • NK cell therapy
  • Immune cell therapies
  • Regenerative medicine
  • Allogeneic cell therapy

Where GI CELL is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

GI CELL business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Technology Licensing / Out-licensing: GI CELL generates revenue by licensing its proprietary NK cell culture technology and T.O.P. NK® platform to international partners. The company receives upfront non-refundable contract fees upon signing, ongoing milestone payments tied to development and regulatory achievements, and double-digit royalties on net sales. Example: Technology export agreement with Turkey's TCT Health Technologies.
  2. CDMO (Contract Development and Manufacturing Organization) Services: GI CELL operates its GMP facility for third-party cell therapy manufacturing. The company holds advanced biopharmaceutical manufacturing and human cell management licenses, enabling it to provide contract manufacturing services to other biotech companies requiring cell therapy production capabilities.
  3. Pharmaceutical / Drug Development: Development of proprietary cell therapy drug candidates (T.O.P. NK, Drone Treg, Nano NK, CAR-NK) targeting cancer and autoimmune diseases. Revenue would be generated upon regulatory approval and commercialization, either independently or through co-development partnerships.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

GI CELL product offering

Product offering

Core offering

GI CELL develops allogeneic (off-the-shelf) immune cell therapies, primarily natural killer (NK) cell and regulatory T cell (Treg) therapies, for the treatment of cancer and autoimmune diseases. The company leverages proprietary feeder-cell-free, non-genetically-modified cell expansion platforms (NKPURE Expander, TregPure Expander, Immune CellPure Expander) to manufacture cell therapy products at commercial scale (world's first 200L NK cell culture). Revenue is generated through technology licensing and out-licensing deals, CDMO services using its GMP-certified smart factory, and planned commercialization of cell therapy drug candidates including T.O.P. NK (GIC-102), GIC-101 (Nano NK), GIC-302 (Drone Treg), and CAR-NK therapies.

Product overview

GI CELL is a cell therapy development company offering a portfolio of immune cell therapy products and platforms. The core product lineup includes T.O.P. NK (GIC-102), an allogeneic NK cell therapy for solid and hematologic cancers in Phase 2a; GIC-101 (Nano NK), an enhanced NK cell therapy with nanoparticle-delivered chemotherapy for solid tumors; GIC-302 (Drone Treg), a patient-customized regulatory T cell therapy for inflammatory bowel disease; and CAR-NK, a next-generation CAR-modified NK cell therapy developed in partnership. These products are underpinned by proprietary technology platforms: the NKPURE Expander Platform (feeder-cell-free NK cell culture), the TregPure Expander Platform (Treg cell culture), and the broader Immune Cell Expander Platform (dual-fusion protein-based immune cell activation and expansion). GI CELL also offers contract development and manufacturing (CDMO) services leveraging its GMP-certified smart factory facility.

Differentiator

Problem solved

Functional benefit

Products and services

  • T.O.P. NK (GIC-102) Allogeneic (off-the-shelf) NK cell therapy for solid tumors and hematologic cancers, produced without feeder cells or viral vectors using the NKPURE Expander Platform. Demonstrates high tumor-targeting and cancer-cell killing efficiency. Currently in Phase 2a clinical trial in Korea after completing Phase 1 with efficacy signals including tumor reduction in a rectal cancer patient (13.5% reduction after 16 weeks) and complete remission in a lymphoma patient who had failed prior antibody and targeted therapy.
  • GIC-101 (Nano NK) Enhanced off-the-shelf NK cell therapy based on the T.O.P. NK platform with chemotherapeutic-loaded nanoparticles attached to the NK cell surface. Leverages NK cell tumor-homing and immunological synapse formation to achieve tumor-specific drug delivery with stronger anticancer effect against solid tumors. Developed using NKPURE Expander Platform in collaboration with POSTECH professor Kim Won-jong.
  • GIC-302 (Drone Treg) Regulatory T cell (Treg) therapy for inflammatory bowel disease and autoimmune conditions, featuring organ-homing receptors (CCR9, α4β7) overexpressed during culture and high FoxP3 expression for targeted treatment. Developed using the TregPure Expander Platform. Targets patients refractory to TNF inhibitors such as Humira and addresses Crohn's disease and ulcerative colitis.
  • CAR-NK Next-generation off-the-shelf CAR-NK cell therapy with chimeric antigen receptor attached, developed in collaboration with HK inno.N, Y-Biologics, and Cartexell. Leverages GI CELL's large-scale NK cell culture and mass production technology combined with partners' antibody discovery platforms for solid tumor targeting.
  • CDMO Contract Manufacturing Services Contract development and manufacturing organization (CDMO) services for third-party cell therapy developers, leveraging GI CELL's GMP-certified smart factory facility (~3,400 m²) and advanced biopharmaceutical manufacturing license. Provides immune cell production capabilities to biotech companies that require cell therapy manufacturing but lack their own GMP infrastructure.

Quantifiable outcome

  • World's first successful 200L NK cell culture in February 2022
  • +5 more outcomes

Companies that use GI CELL

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles3 records

GI CELL technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

GI CELL partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • TCT Health Technologies (Türkiye)coreStrategic or Co-development Partner · 21 November 2024GI CELL signed a letter of intent with TCT Health Technologies, a Turkish venture capital investment fund, for technology export of its allogeneic NK cell therapy (T.O.P. NK®). TCT will have commercialization rights in Turkey and neighboring CIS countries, bearing all development and clinical costs. GI CELL receives non-refundable upfront fees and double-digit royalties on net sales. Agreement for definitive technology transfer contract planned for March 2025. Led by Dr. Adil Mardinoglu, CSO of TCT and Professor at King's College London.
  • Y-Bio Logics (와이바이오로직스)coreStrategic or Co-development Partner · 22 July 2024GI CELL and Y-Bio Logics signed a business cooperation agreement (MOU) for co-development of CAR-NK anticancer therapy candidates. Y-Bio Logics contributes its antibody discovery platform technology and nanobody library (Ymax-ABL, Ymax-Nano, pH-sensitive antibody technology, ALiCE T-cell bispecific platform) to develop novel tumor-targeting CAR-NK products combined with GI CELL's NK cell expansion and mass culture capabilities.
  • OmniaMed (옴니아메드)minorStrategic or Co-development Partner · 2 November 2023GI CELL participates as co-development partner in a Ministry of Trade, Industry and Energy-funded cross-disciplinary technology project with OmniaMed. OmniaMed is developing PNP (polymer nanoparticle) mRNA delivery platform technology; GI CELL contributes its NK cell therapy platform to develop next-generation allogeneic NK cell therapy with enhanced anticancer activity and in-vivo persistence through mRNA delivery technology. Project selected April 2023.
  • HK inno.N (HK이노엔)coreStrategic or Co-development Partner · 29 August 2022GI CELL and HK inno.N entered a joint R&D agreement for allogeneic CAR-NK candidate development. The partnership leverages GI CELL's large-scale immune cell culture technology and HK inno.N's development and commercialization experience. Companies plan to develop multiple CAR-NK programs targeting clinical entry by 2024. HK inno.N brings GMP facilities and extensive pharmaceutical development capabilities.
  • HelixmithminorStrategic or Co-development Partner · 27 April 2022GI CELL signed MOU with Helixmith and Cartexell for joint development of innovative cell therapies using the Immune Cell Expander Platform. Collaboration involves joint research on gene materials needed for cell therapy development, with potential for separate contract manufacturing agreements.
  • CartexellminorStrategic or Co-development Partner · 27 April 2022GI CELL signed MOU with Helixmith and Cartexell for joint development of innovative cell therapies using the Immune Cell Expander Platform. Collaboration involves joint research on gene materials needed for cell therapy development.
  • Yonsei University Health System / Severance Hospital (연세대학교 의료원/세브란스병원)coreStrategic or Co-development Partner · 2 March 2022GI Innovation, GI CELL, and Yonsei University Health System signed MOU to establish a cell therapy center at Severance Hospital and Songdo Severance Hospital. The partnership aims to build GMP facilities within hospital sites and establish a seamless process for research, production, clinical trials, and regulatory approval of advanced biopharmaceuticals including cell therapies.
  • Ewha Womans University Medical Center (이화여자대학교 의료원)minorStrategic or Co-development Partner · 18 May 2021GI CELL and Ewha Womans University Medical Center signed MOU for biohealth industry promotion and development. Cooperation areas include anticancer immune cell therapy translational and clinical research, COVID-19 vaccine candidate development, clinical trial consulting, and new drug co-research.
  • International Vaccine Institute (IVI, 국제백신연구소)minorStrategic or Co-development Partner · 25 January 2021GI CELL signed MOU with IVI for co-development of COVID-19 vaccine candidate. IVI facilitates international clinical development and global supply of vaccines. GI CELL contributes its vaccine development capabilities. The partnership targets vaccine development with variant responsiveness, safety, and patient convenience.
  • GI Innovation Group / Yonsei University College of Medicine (지아이그룹/연세대학교 의과대학)coreStrategic or Co-development Partner · 5 January 2021GI Innovation, GI CELL, GI Biome, and Yonsei University College of Medicine signed MOU for innovative new drug development. GI CELL contributes immune cell therapy expertise; Yonsei contributes clinical research capabilities. Partnership includes joint research center establishment, academic conferences, and joint seminars.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

GI CELL competitors and assessment

Company assessment

Direct peers

  • Nkarta Therapeutics: Clinical-stage biotech developing allogeneic NK cell therapies for cancer using engineered NK cells. Direct competitor in allogeneic NK cell therapy modality with overlapping target indications in solid tumors and hematologic malignancies.
  • Fate Therapeutics: Clinical-stage biotech developing off-the-shelf iPSC-derived NK cell and T-cell therapies. Closely comparable in modality (off-the-shelf allogeneic cell therapy) and target indications, with established partnerships with major pharma companies.
  • Century Therapeutics: Clinical-stage company developing allogeneic cell therapies including NK and T cells derived from iPSCs. Direct competitor in off-the-shelf engineered cell therapy for oncology with comparable pipeline stage and target indications.
  • Shoreline Biosciences: Developer of allogeneic NK cell and macrophage cell therapies derived from iPSCs. Competes directly with GI CELL in the allogeneic NK cell therapy space with platform technology focused on scalable off-the-shelf production.
  • Cellectis: Clinical-stage biotech developing allogeneic CAR-T and other engineered cell therapies using gene editing. Comparable in developing off-the-shelf cell therapies, though focused on T cells with TALEN gene editing technology.
  • Atara Biotherapeutics: Allogeneic T-cell immunotherapy company with marketed product Ebvallo and pipeline in oncology and autoimmune. Comparable in allogeneic off-the-shelf cell therapy modality and target indications including autoimmune disease.

Broad incumbents

  • Adaptimmune Therapeutics: Commercial-stage cell therapy company developing engineered T-cell therapies for solid tumors with approved product Tecelra. Broader incumbent in cell therapy space with overlapping oncology focus and established manufacturing capabilities.
  • Crispr Therapeutics: Clinical-stage gene editing company developing gene-edited cell therapies including allogeneic CAR-T candidates. Operates more broadly across gene editing modalities but overlaps in engineered cell therapy development for oncology.
  • Kite Pharma (Gilead Sciences): Established commercial cell therapy leader with approved CAR-T products Yescarta and Tecartus. Larger industry incumbent serving as both a competitor and potential acquirer/partnership target for next-generation cell therapy developers.

Others

  • GI Innovation: Parent company of GI CELL and developer of fusion protein-based biopharmaceuticals. Closely related entity providing the dual-function cytokine fusion protein technology that underpins GI CELL's cell expansion platforms, also a strategic partner.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

GI CELL social profiles

Digital presence

GI CELL compliance and trust

Trust signal

Compliance7 records

GI CELL financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GI CELL leadership team

Management profile

Number of profiles

Profiles6 records

GI CELL funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GI CELL M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GI CELL

What does GI CELL do?

GI CELL develops allogeneic (off-the-shelf) immune cell therapies, primarily natural killer (NK) cell and regulatory T cell (Treg) therapies, for the treatment of cancer and autoimmune diseases. The company leverages proprietary feeder-cell-free, non-genetically-modified cell expansion platforms (NKPURE Expander, TregPure Expander, Immune CellPure Expander) to manufacture cell therapy products at commercial scale (world's first 200L NK cell culture). Revenue is generated through technology licensing and out-licensing deals, CDMO services using its GMP-certified smart factory, and planned commercialization of cell therapy drug candidates including T.O.P. NK (GIC-102), GIC-101 (Nano NK), GIC-302 (Drone Treg), and CAR-NK therapies.

Is GI CELL a public or private company?

GI CELL is a private company. It is classified as venture growth investor backed and is currently operating.

When was GI CELL founded?

GI CELL was founded in 2018. It employs 11 to 50 people.

Where is GI CELL based?

GI CELL is headquartered in Seongnam, South Korea, in the Asia region.

How does GI CELL make money?

Three revenue lines are on record. Technology Licensing / Out-licensing is the primary driver. The others are CDMO (Contract Development and Manufacturing Organization) Services and pharmaceutical / Drug Development.

Who are GI CELL's main competitors?

Direct peers on record are Nkarta Therapeutics, Fate Therapeutics, Century Therapeutics, Shoreline Biosciences, Cellectis and Atara Biotherapeutics. Broad incumbents are Adaptimmune Therapeutics, Crispr Therapeutics and Kite Pharma (Gilead Sciences). GI Innovation is listed as an others.

Does GI CELL have an API?

No public API is recorded for GI CELL.

What industry is GI CELL in?

GI CELL's product category is Cell Therapy / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales